What question did this study set out to answer?

To evaluate the effects of early baricitinib and selective plasma exchange (SePE) in patients with anti-MDA5 DM-associated interstitial lung disease.

May 20, 2026American Journal of Respiratory and Critical Care Medicine

D103-02 Early Introduction of Baricitinib Combined With Repeated Selective Plasma Exchange for Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Two-case Series

View Full Paper

Ask AI

Bookmark

To evaluate the effects of early baricitinib and selective plasma exchange (SePE) in patients with anti-MDA5 DM-associated interstitial lung disease.
Case series involving two patients with anti-MDA5 DM-associated ILD receiving baricitinib and SePE.
SePE performed 19 times over 12 weeks for one patient and 17 times over 6 weeks for the other patient.
High-dose corticosteroids and other immunosuppressants were administered alongside treatment.
Significant reduction in ferritin and anti-MDA5 antibody titers in both cases.
Patients maintained stable oxygenation and avoided respiratory failure throughout treatment.
Clinical improvement in dermatomyositis symptoms and pulmonary findings noted for both patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Case series demonstrates early baricitinib and plasma exchange improves outcomes in anti-MDA5 dermatomyositis-associated ILD, suggesting new treatment options.

Cite This Study

Okamori et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f34f03e14405aa9a6b1 https://doi.org/10.1093/ajrccm/aamag162.2892

View Full Paper

Ask AI

Bookmark

Implication

Case series demonstrates early baricitinib and plasma exchange improves outcomes in anti-MDA5 dermatomyositis-associated ILD, suggesting new treatment options.

D103-02 Early Introduction of Baricitinib Combined With Repeated Selective Plasma Exchange for Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Two-case Series

Key Points

Discussion

Implication

Cite This Study

D103-02 Early Introduction of Baricitinib Combined With Repeated Selective Plasma Exchange for Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Two-case Series

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider